DNA Nanobots today announced the close of its pre-seed investment to grow its DNA nanoparticle platform for targeted delivery of therapeutic payloads.

Nutcracker Therapeutics and Elegen see their mission as delivering scalable and low-cost RNA manufacturing for individualized therapies.

A research team led by Dr. Hye sun Cho at the Plant Systems Engineering Research Center of the Korea Research Institute of Bioscience and Biotechnology(KRIBB) has uncovered, for the first time at the ...